The 2026 Peptide Tier List: 48 Compounds Ranked S to F by Evidence

Why a tier list — and why evidence is the only axis that matters

Search "best peptides" and you'll get rankings built on Reddit anecdotes, influencer stacks, and vendor copy. They sort by vibes. The PepCue tier board sorts by one thing: how much human evidence exists that the compound does what people claim, and whether a regulator has actually reviewed it.

That distinction is not pedantic. A compound that lowered major adverse cardiovascular events in a 17,604-person randomized trial belongs in a different universe from one whose entire reputation rests on tendon-healing experiments in rats. Both get called "peptides." Both get sold. Only one has earned the claim. A tier list is the fastest way to make that gap legible at a glance — which is exactly why we built one, and why every tier below is defined by evidence quality, not popularity.

A blunt caveat up front: this article discusses evidence and mechanism only. It contains no doses, protocols, cycles, or how-to instructions. Many compounds on the lower tiers are research chemicals that are not approved for human use, and ranking a compound on the board is not an endorsement of taking it.

How PepCue grades a compound (the methodology)

Every compound on the board is scored against four questions, in descending order of weight:

1. Is there randomized, controlled human data? An RCT — ideally large, blinded, placebo-controlled, and published in a peer-reviewed journal — is the gold standard. Animal studies, cell-culture work, and mechanistic plausibility do not substitute for it. This is the single biggest lever on a compound's grade.

2. Is it approved by a regulator, and for what? FDA (or EMA) approval means a defined indication cleared a rigorous benefit-risk review. Crucially, approval is indication-specific: a peptide approved for one condition is not validated for the off-label uses it's marketed for online.

3. How big is the gap between the claim and the evidence? A compound can have real preclinical data and still be wildly oversold. We penalize the distance between "what a rat study showed" and "what the label on the vial implies."

4. What is the regulatory and safety status? Research-only status, anti-doping bans, and active FDA safety flags all pull a grade down — not because they prove a compound is dangerous, but because they signal the human safety package is incomplete.

The tiers map cleanly onto those questions. S = approved, RCT-grade, outcome data. A = approved or late-stage human RCTs for the relevant use. B = early but real human trials. C = thin or proxy-only human data. D = essentially preclinical, heavily oversold. F = near-zero human data, sometimes safety-flagged.

S-Tier: approved, RCT-grade, outcomes you can bank on

S-tier is reserved for compounds with large randomized trials, regulatory approval, and — in the best cases — hard outcome data, not just surrogate markers.

Semaglutide is the cleanest example. In the SELECT trial, published in the New England Journal of Medicine in 2023, once-weekly semaglutide reduced the risk of major adverse cardiovascular events (cardiovascular death, nonfatal heart attack, or nonfatal stroke) by roughly 20% versus placebo in more than 17,600 adults with overweight or obesity and established cardiovascular disease but without diabetes. That is an outcome trial — not weight on a scale, but heart attacks and strokes prevented. Semaglutide is FDA-approved as Ozempic (type 2 diabetes, 2017) and Wegovy (weight management, 2021).

Tirzepatide, a dual GIP/GLP-1 receptor agonist, sits beside it. In SURMOUNT-1 (NEJM, 2022), participants without diabetes lost on average 16.0% to 22.5% of body weight across doses over 72 weeks, versus 2.4% on placebo — among the largest weight reductions ever recorded for a pharmacologic agent. It's approved as Mounjaro and Zepbound.

Tesamorelin earns S-tier on a narrow but real claim: it is a synthetic GHRH analog FDA-approved (as Egrifta, 2010) specifically to reduce excess visceral abdominal fat in HIV-associated lipodystrophy, backed by Phase 3 trials. Note the precision — it is approved for that population and that indication, not as a general-purpose body-composition or anti-aging peptide, which is how it's frequently marketed.

Older GLP-1 liraglutide (Victoza for diabetes; Saxenda, approved 2014, for weight) and bremelanotide (Vyleesi, a melanocortin agonist FDA-approved in 2019 for hypoactive sexual desire disorder in premenopausal women) also clear the S/A line on the strength of approval plus randomized data — though bremelanotide's effect size was modest, with roughly 25% of treated women hitting a desire-score threshold versus 17% on placebo.

A and B-Tier: real human trials, but the story isn't finished

Below the approved tier sit compounds with genuine, sometimes spectacular human data that simply haven't crossed the finish line — or whose long-term safety package is still being assembled.

Retatrutide is the marquee example and the most-hyped peptide of the moment with actual receipts. It's a triple agonist hitting GLP-1, GIP, and glucagon receptors. In a Phase 2 trial (Jastreboff et al., NEJM, 2023; PMID 37366315), participants on the highest dose lost about 24% of body weight at 48 weeks versus roughly 2% on placebo. That is extraordinary — but it is Phase 2, not approval. Phase 3 outcome trials are ongoing, and a drug is not validated until those read out. Retatrutide belongs in A-tier as a high-confidence candidate, not S-tier as a settled one.

This tier is also where honesty about indication matters. Many GLP-1-class and incretin compounds have strong data for metabolic endpoints but are sold for adjacent claims (muscle, longevity, "recovery") that the trials never tested. A B-tier grade often means "the human data is real, but for a narrower thing than the marketing implies."

C and D-Tier: where preclinical data gets dressed up as proven

The middle-lower tiers are where the human-versus-animal gap does the most damage to consumers — because these compounds have just enough science to sound credible.

AOD-9604, a fragment of growth hormone marketed for fat loss, is the textbook case. In obese mice, it increased fat oxidation and reduced weight gain. That preclinical story powered a decade of marketing. But in humans it underperformed: across roughly six Phase 1/2 trials enrolling around 900 people, it showed a reassuring safety profile but failed to demonstrate convincing, statistically robust weight loss, and clinical development was ultimately abandoned. AOD-9604 is a compound where the animal data is real and the human efficacy data is, charitably, unconvincing — a D-tier signature.

The broader pattern: a compound lands in C/D when its human evidence is a single small trial, a surrogate-marker study, or nothing but mechanism plus mouse data. Mechanistic plausibility is not proof. "It activates pathway X in cells" tells you nothing about whether a human gets a meaningful, safe benefit.

F-Tier: near-zero human data — and that's the honest grade

F-tier is the largest and most-trafficked region of the peptide market, which is the uncomfortable truth the tier list exists to surface.

BPC-157 is the headline. It is genuinely popular and genuinely under-evidenced in humans: a 2025 systematic review of its orthopedic use screened over 500 articles and found essentially one clinical study, with the rest preclinical animal models. There is, in the words of regulatory science, little to no reliable human evidence for its safety or efficacy. It carries regulatory baggage too — the FDA placed it in Category 2 of its interim 503A bulk-substances list in 2023 (later removed in April 2026, which changes its compounding status but not the underlying thinness of human trials), and the World Anti-Doping Agency added it to the Prohibited List in 2022. Robust animal data plus near-zero human RCTs is the definition of F-tier, regardless of how good the testimonials sound.

The longevity-peptide cluster — epitalon, MOTS-c, humanin, and most "anti-aging" mitochondrial peptides — lives here too. These have intriguing mechanisms and cell or animal data, but no large randomized human trials and no approval for longevity use. GHK-Cu is a partial exception with reasonable human data for topical skin effects, which is why it grades higher than its longevity-stack neighbors — a reminder that grades are claim-specific. The unifying F-tier feature is simple: if you remove the rat studies and the mechanism diagrams, almost nothing is left.

How to read the board without fooling yourself

A few rules turn the tier list from a leaderboard into a literacy tool.

Approval is not transferable. Tesamorelin being approved for HIV lipodystrophy says nothing about its safety or benefit as a general anti-aging compound. Always ask: approved for whom, for what?

Phase 2 is a promise, not a verdict. Retatrutide's numbers are stunning, but drugs fail in Phase 3 routinely — for safety, for durability, for effects that shrink in larger populations. A spectacular small trial earns optimism, not certainty.

Mechanism is the weakest evidence, not the strongest. The compounds with the most elaborate mechanistic stories told online (BPC-157, the longevity peptides) are frequently the ones with the least human data. Vendors lead with mechanism precisely because they have no outcomes to show.

Research-only means the human safety package is incomplete. "Not for human consumption" labeling exists for a reason. An F or D grade is not a dare; it's a flag that nobody has done the work to know.

The single most useful habit: before believing any peptide claim, find the largest human trial that tested that exact claim. If it doesn't exist, you've found the tier — and it's near the bottom of the board.